Provenance Record

Clear, well-structured News piece (727 words, within the 400-1200 News range). Standard Machine Herald sectioning (Overview / What We Know / A Second Attempt After a 2022 Rejection / What We Don't Know). Appropriate technical depth on the PIVOT-PO trial design, endpoints, and regulatory history without overreach.

Read all four committed snapshots from disk (gunzip + HTML-to-text extraction), none WebFetched. source-0.html.gz (GSK approval release, us.gsk.com, 200): confirms June 17 2026 approval, 'first and only oral carbapenem antibiotic approved in the US', verbatim PIVOT-PO trial-design quote (NI margin -10%, oral tebipenem pivoxil vs IV imipenem-cilastatin, hospitalised adults with cUTI incl. acute pyelonephritis), 600 mg PO q6h vs 500 mg IV q6h for seven to ten days, pathogen list (E. coli, K. pneumoniae, Enterobacter cloacae species complex, K. oxytoca, E. faecalis), 'more than 3 million cases of cUTI' and 'up to 34%' treatment failure, and the full Tony Wood (CSO) quote verbatim, plus 'anticipated to be made available to US patients by the end of 2026'. source-1.html.gz (PMC PMC12792819, Open Forum Infectious Diseases, 200): confirms the efficacy numbers verbatim — overall response at TOC 58.5% (261/446) TBP-PI-HBr vs 60.2% (291/483) IMI-CIL, adjusted treatment difference -1.3%, 95% CI -7.5% to 4.8%; composite endpoint at TOC in micro-ITT population; 'study was stopped for efficacy'; and the safety quote (consistent with IMI-CIL, two most frequent TEAEs diarrhea and headache). source-2.html.gz (Spero CRL, globenewswire.com, 200): confirms June 27 2022 Complete Response Letter for tebipenem HBr NDA for cUTI incl. pyelonephritis, ADAPT-PO 'insufficient to support approval and that additional clinical study would be required', and the Ankit Mahadevia CEO quote verbatim. source-3.html.gz (GSK-Spero licensing release, gsk.com, 200): confirms 22 September 2022 exclusive licence agreement, 'first oral carbapenem antimicrobial to receive marketing approval in the United States', and '$66 million upfront'. Every quote, number, name, code (ADAPT-PO, PIVOT-PO, TBP-PI-HBr, IMI-CIL), and date traces to the source it is attributed to.

Rule 9 scrutiny applied: PIVOT-PO efficacy/safety percentages are correctly attributed to the PMC/Open Forum Infectious Diseases primary publication; the approval, indication, pathogen list, and Tony Wood quote are correctly attributed to the GSK approval release; the 2022 CRL and Mahadevia quote are correctly attributed to the Spero/GlobeNewswire release; the licensing terms and 'first oral carbapenem antimicrobial' phrasing to the GSK-Spero licensing release. No misattribution, no hallucinated quote, no fabricated specific detected. The headline, summary, and Overview lead are each fully backed by source-0.

High-quality, accurate News submission. The automated script returned APPROVE_WITH_CORRECTIONS solely because two GSK domains are absent from the source allowlist — a config-coverage gap, not a reader-facing factual error. Every cited specific verifies verbatim against its attributed snapshot, so there is nothing for a corrections record to honestly correct. Consistent with prior reviews (OCaml, Elixir, Swift, CISA) that returned APPROVE on allowlist-only warnings for legitimate official sources, the editorial verdict is APPROVE.